<DOC>
	<DOCNO>NCT01988246</DOCNO>
	<brief_summary>To determine safety efficacy intravitreal Aflibercept ( Eylea ) injection patient diabetic retinopathy prevention macular edema follow cataract surgery .</brief_summary>
	<brief_title>Prevention Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery</brief_title>
	<detailed_description>Diabetic retinopathy patient risk develop macular edema ( define ≥ 30 % increase pre-operative baseline central subfield macular thickness ) within 90 day follow cataract surgery . Diabetic patient define either Type 1 Type 2 diabetes . The patient must either mild , moderate , severe non proliferative retinopathy treat proliferative retinopathy . Patients must 18 year age old , race either sex , require cataract extraction plan implantation posterior chamber intraocular lens lens capsule .</detailed_description>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<criteria>A patient must meet follow criterion eligible inclusion study : 1 . Must 18 year age old , race either sex , cataract , plan undergo cataract extraction phacoemulsification implantation posterior chamber intraocular lens lens capsule 2 . History Type I Type II diabetes 3 . NPDR : nonproliferative diabetic retinopathy ( mild , moderate , severe ) inactive proliferative disease study eye define International Clinical Diabetic Retinopathy Disease Severity Scale 4 . Willing able comply clinic visit studyrelated procedure 5 . Patients must able understand sign informed consent approve Institutional Review Board ( IRB ) 6 . Central subfield macular thickness ≤ 320 μm study eye prior cataract surgery determine SDOCT confirm read center 7 . Absence clinically significant macular edema ( CSME ) study eye detect clinical exam 8 . Patients must visual acuity 20/2020/200 A patient meet follow criterion exclude study : 1 . Signs vitreomacular traction epiretinal membrane study eye detect read center investigator 2 . Current previous ocular disease study eye opinion investigator may confound assessment macula , retina , central vision diabetic retinopathy 3 . Active proliferative diabetic retinopathy study eye 4 . Planned multiple procedure study eye cataract/IOL implantation surgery ( e.g. , trabeculectomy , corneal transplant ) 5 . Patients receive corneal transplant study eye 6 . Patients current history chronic recurrent ocular infection inflammation study eye 7 . Patients visually nonfunctional fellow eye base upon assessment investigator 8 . Patients immunocompromised ( e.g. , patient receive chemotherapy irradiation therapy , patient AIDS , leukemia , cachexia ) patient receive dialysis 9 . Use medication know affect macula , include hydroxychloroquinine ( Plaquenil ) phenothiozines ( e.g. , thioridazine [ Mellaril ] , chloropromazine [ Thorazine ] ) supplemental niacin ≥3 grams/day 10 . Use systemic steroid , NSAIDS ( nonsteroidal antiinflammatory drug ) , antiVEGF agent within 7 day prior surgery ( study exit ) . Daily dose aspirin , 325 mg , permit . 11 . Use topical ocular NSAIDS steroid , study eye , within 7 day prior surgery 12 . Treatment intraocular periocular steroid study eye within 3 month prior surgery 13 . Focal photocoagulation treatment diabetic macular edema study eye within 6 month preoperative baseline visit ( Note : peripheral retina treatment retinal tear lattice degeneration permit ) 14 . Intravitreal antiVEGF ( vascular endothelial growth factor ) treatment study eye within 6 month preoperative baseline visit 15 . Patients know hypersensitivity NSAIDs steroid component study medication . 16 . Use topical ophthalmic prostaglandin ( e.g. , TRAVATAN , XALATAN ) within 4 day surgery study exit 17 . Any concurrent intraocular condition study eye , opinion investigator , could require either medical surgical intervention 90 day study period . 18 . Any concurrent ocular condition study eye , opinion investigator , could either increase risk patient beyond expect standard procedure intraocular injection , otherwise may interfere injection procedure evaluation efficacy safety . 19 . Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Diabetic Retinopathy</keyword>
</DOC>